RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on August 09, 2005 has allotted 2,02,837 Equity Shares on exercise of stock options under the Employee Stock Option Scheme(s) of the Company. The Paid-up Equity Share Capital of the Company post allotment is 372393877 Equity Shares of Rs. 5 each aggregating Rs. 1861969385.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 28, 2005, titled "Ranbaxy Gains Tentative approval to market additional strengths of Glimepiride Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 28, 2005, titled "Ranbaxy Global Sales at USD 309 MN, Records 11% growth". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of Minutes of the AGM of the Company held on June 30, 2005. The details of the same shall be be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Clarification of News : The press had reports that Ranbaxy Laboratories Limited is in advanced stages of acquiring a south-based domestic pharma firm. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "As part of our overall strategy for growth and expansion, we do evaluate various opportunities from time to time. However, as far as the above news item i

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on August 03, 2005, titled "Ranbaxy receives tentative approval to market Sumatriptan Succinate Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 02, 2005, titled 'Ranbaxy Sets Up Additional Manufacturing Facility In Malaysia; Prepares To Meet Growing Demand For Generics In the Asean Region', being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. Ravi Mehrotra who was appointed as a Director of the Company on July 28, 2005, does not hold any shares of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on July 28, 2005 has approved the appointment of Mr. Ravi Mehrotra as an Additional Director on the Board of Directors of the Company w.e.f. July 28, 2005, Mr. Mehrotra is the President for Franklin Templeton Asset Management (India) Pvt. Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has on July 25, 2005, announced that Nihon Pharmaceutical Industry Ltd. (NPI), a Joint Venture between RLL and Nippon Chemiphar Limited (NC), has launched its first co-developed product, Vogseal 0.2mg and 0.3mg tablets (Generic-Voglibose) in Japan. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company on July 21,2005 titled "Ranbaxy gains tentative approval to market Glimepiride tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 14,2005 titled "Ranbaxy receives USFDA approval for Zidovudine Tablets". The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company on July 05,2005 titled "Ranbaxy to market Doktor Mom Herbal brand range manufactured by J.B.Chemcials, in Romania" . The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 04,2005 titled "Ranbaxy gains approval to market METFORMIN XL Tablets,750 mg-Representing 100th ANDA approval held by Ranbaxy". The details of the press release are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange as follows: 1) The Shareholders of the Company at the AGM held on June 30, 2005 inter-alia have approved sub-division of equity shares of the company from face value of Rs.10 per share to Rs.5 per share; 2) The company has fixed August 01, 2005 as the Record Date for sub-division of the equity shares of the company from face value of Rs.10 per share to Rs.5 per share.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled "Ranbaxy receives tentative approval to market Terbinafine Hydrochloride 250 MG Tablets", being issued by the Company on June 22, 2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled "Ranbaxy Pharmaceuticals Inc.,USA,receives prestigious outstanding supplier award from WAL-MART" being issued on June 21,2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that with reference to the news item titled 'Ranbaxy in talks to buy stake in Ind-Swift', appearing in Economic Times of June 10, 2005 the Company has informed that: 1)The news item that Ranbaxy is in talk to buy into Ind-Swift is baseless and without any substance and does not deserve any comment. 2) In regard to acquisition of 18 products from Spanish pharmaceutical company EFARMES, S.A., the company issued a press release on June 09, 2005. 3) In regard to the court case relating to Lipitor, the news of an out of court settlement with Pfizer

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled 'RANBAXY ACQUIRES GENERIC PRODUCT PORTFOLIO FROM EFARMES OF SPAIN', being issued by the Company. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd. has submitted to the Exchange a copy of the notice of AGM of the Company to be held on June 30, 2005. A copy of the notice of the AGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 02, 2005, titled "Ranbaxy's Goa (India) Manufacturing Plant Receives MHRA, UK Approval", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 31, 2005, titled "RANBAXY RECEIVES INDIA'S FIRST APPROVAL FROM USFDA FOR AN ANTI RETROVIRAL DRUG UNDER THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF INITIATIVE (PEPFAR)", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 27, 2005, titled "RANBAXY HIV UPDATE". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 24, 2005, titled "RANBAXY ANNOUNCES THE LAUNCH OF CLARITHROMYCIN IR 250 MG and 500 MG TABLETS IN USA", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated May 12, 2005 titled "Ranbaxy HIV Update - May 2005." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the sale and purchase of the shares by Ranbaxy Holding Company as follows: Ranbaxy Holding Company has (i) acquired 30,50,262 shares aggregating to 1.639% of the share capital of Ranbaxy Laboratories Ltd. by way of market purchases; (ii) acquired 6,94,444 shares aggregating to 0.373% of the share capital of Ranbaxy Laboratories Ltd. by way of pledge; and (iii) sold 134 shares of Ranbaxy Laboratories Ltd. The period of the said acquisition / sale is between March 04, 2005 to April 15, 2005 and the shareholding of Ranbaxy Holding Compa

Rabo India Finance Pvt. Limited has informed the Exchange that a pledge has been created on 9,836,065 shares of Ranbaxy Laboratories Limited in their favour during the period between January 20,2005 to April 28,2005.The details of the same are as follows: Rabo India Finance Pvt. Ltd. have acquired 605,295* shares aggregating to 0.33% of the total paid up capital of Ranbaxy Laboratories Limited on April 28, 2005. The mode of acquisition is by way of pledge and the shareholding of Rabo India Finance Pvt. Ltd. after the said acquisition is 9,836,065* shares aggregating to 5.29% of the total paid

Ranbaxy Laboratories Ltd has informed the Exchange that they have received disclosure from M/s. Rabo India Finance Pvt. Ltd., consequent to Pledge created on 9,836,065 shares of Ranbaxy Laboratories Ltd. during the period between January 20, 2005 and April 28, 2005. The details of the same are as follows: Rabo India Finance Pvt. Ltd. (Pledgee) has acquired 605,295* shares aggregating to 0.33% of the total paid up capital of Ranbaxy Laboratories Ltd. on April 28, 2005. The mode of acquisition is by way of pledge and the shareholding of Rabo India Finance Pvt. Ltd after the said acquisition is 9

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated April 28,2005 titled "Ranbaxy Q1,05 Global Sales at USD 261 Mn - Board recommends Final dividend of Rs 12 per share for 2004, Announces Stock Split " . The details of the press release are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the BOD at its meeting held on April 28, 2005, have approved the following: 1) The Board has recommended a final dividend of Rs.12 per share for the year ended December 31, 2004 taking the total dividend for the year to Rs.17 per share. 2) Share transfer books will remain closed from June 18, 2005 to June 30, 2005 (both days inclusive) for the purpose of determination of entitlement of Final Dividend. 3) Annual General Meeting has been fixed for June 30, 2005. 4) To seek approval of the shareholders at the ensuing Annual General meeting f

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. S.K.Patawari, Company Secretary of the Company, has acquired 608 shares of Ranbaxy Laboratories Ltd on April 12, 2005. The mode of acquisition is ESOP Allotment and the shareholding of Mr. S.K.Patawari after the said acquisition is 4798 shares of Ranbaxy Laboratories Ltd..

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has entered into a collaborative agreement with the National Chemical Laboratories (NCL), Pune and the Department of Science & Technology (DST), New Delhi, in the area of New Drug Discovery. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated April 12, 2005, titled 'RANBAXY VOLUNTARILY DISCONTINUES VALDECOXIB FOLLOWING USFDA's CAUTIONARY VIEWS ON INNOVATOR PFIZER's BEXTRA'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment committee of Directors at its meeting held on April 11, 2005 has allotted 1,11,710 Equity Shares on exercise of stock options under the Employees Stock Option Scheme of the Company. The paid-up Equity Share Capital of the Company post allotment will be Rs.1860955200.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V. K. Kaul, Director of the Company, has sold 10,400 shares of Ranbaxy Laboratories Ltd on March 24. 2005. The mode of sale is market sale and the shareholding of Mr. V. K. Kaul after the said sale is 43,600 shares aggregating to 0.02% of the share capital of Ranbaxy Laboratories Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release titled "Joint Announcement by Ranbaxy(UK) Ltd. and The Department of Health" on April 01,2005. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release titled "Ranbaxy receives FDA Approval to Market a Generic Alternative to Macrobid� on April 01,2005. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated March 29, 2005, titled 'Austrian Patent Office issues favourable ruling for Ranbaxy on Atorvastatin - Pfizer's patent claims for enantiomeric form held invalid.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated March 30, 2005, titled 'Ranbaxy to Appeal Preliminary Injunction Against Sales of Quinapril.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated March 23, 2005 tilted "Ranbaxy HIV Update-March 2005". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that with reference to the News Item appearing in the Economic Times dated March 11, 2005 titled "Promoters increase stake in Ranbaxy Labs", the Company has clarified that the aforesaid news item has wrongly mentioned the promoters stake in the company as 25.59%.The aggregate equity holding of the promoters in the company per disclosure made by the company to the stock exchanges on March 09,2005 was 33.93% of the total share capital of the company.

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a press release dated March 11,2005 titled "Ranbaxy announces new structure for research & development focus on dual areas of drug discovery and Generics/NDDS/Drug Development". The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Corporate office of the Company has shifted at the following address: Ranbaxy Laboratories Ltd, Plot No.90, Sector-32, Gurgaon - 122001 (Haryana), India. Phone:+91-124-5135000 Fax No:+91-124-5135001.

Ranbaxy Laboratories Ltd has informed the Exchange that Ranbaxy Holding Company, which is under control of Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh, Promoters of Ranbaxy Laboratories Limited, have acquired 37,19,676 shares aggregating 2.00% of the total paid up capital of Ranbaxy Laboratories Ltd. during the period June 25, 2004 to March 04, 2005, and sold 6052 shares of Ranbaxy Laboratories Limited during the period August 17, 2004 to September 09, 2004. The mode of acquisition / sale is through the Open Market and the shareholding of Ranbaxy Holding Company after the said acqu

Ranbaxy Laboratories Ltd has informed the Exchange that the following entities under control/acting in concert with Malvinder Mohan Singh and Shivinder Mohan Singh, Promoters of Ranbaxy Laboratories Limited have acquired/sold shares of Ranbaxy Laboratories Limited, as detailed below: 1) Ranbaxy Holding Company has purchased 35,94,633 shares aggregating 1.93% of the total paid up capital of the Company; 2) Oscar Investments Ltd. has purchased 125,043 shares aggregating 0.07% of the total paid up capital of the Company; 3) Ranbaxy Holding Company has sold 6,052 shares of the Company; 4) Analytic

Malvinder Mohan Singh and Shivinder Mohan Singh, Promoters of Ranbaxy Laboratories Limited, have informed the Exchange that the following entities under control/acting in concert with them have acquired/sold shares of Ranbaxy Laboratories Limited, as detailed below: 1) Ranbaxy Holding Company has purchased 35,94,633 shares aggregating 1.93% of the share capital of the Company; 2) Oscar Investments Ltd. has purchased 125,043 shares aggregating 0.07% of the share capital of the Company; 3) Ranbaxy Holding Company has sold 6,052 shares of the Company; 4) Analytical Testing Services P Ltd. has sol

Ranbaxy Holding Company, which is under control of Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh, Promoters of Ranbaxy Laboratories Limited, have informed the Exchange that they have (i) acquired 37,19,676 shares aggregating 2.00% of the total paid up capital of Ranbaxy Laboratories during the period June 25, 2004 to March 04, 2005, and (ii) sold 6052 shares of Ranbaxy Laboratories Limited during the period August 17, 2004 to September 09, 2004. The mode of acquisition / sale is through the Open Market and the shareholding of Ranbaxy Holding Company after the said acquisition / sale

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued a press release dated February 01, 2005 titled 'Ranbaxy receives final approval for Clarithromycin XL 1000 MG Tablet'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has made three fresh filings of its Anti-Retrovirals (ARVs) agents, to the WHO for its approvals. The details of the press release titled 'Ranbaxy HIV update - January 24, 2005' shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd. has informed the Exchange that the company has on January 21,2005 issued a press release titled "Ranbaxy strengthens Top Management team to meet 2007 target of USD 2 Bn". The details of the press release are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).